RT Journal Article
SR Electronic
T1 Acceptance of COVID 19 vaccine among sub-Sahara African (SSA): a comparative study of residents and diaspora dwellers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.16.22272510
DO 10.1101/2022.03.16.22272510
A1 Miner, Chundung Asabe
A1 Timothy, Chikasirimobi G.
A1 Mashige, Khathutshelo Percy
A1 Osuagwu, Uchechukwu Levi
A1 Envuladu, Esther Awazzi
A1 Amiebenomo, Onyekachukwu Mary-Anne
A1 Ovenseri-Ogbomo, Godwin
A1 Charwe, Deborah Donald
A1 Goson, Piwuna Christopher
A1 Ekpenyong, Bernadine N
A1 Abu, Emmanuel Kwasi
A1 Langsi, Raymond
A1 Oloruntoba, Richard
A1 Ishaya, Tanko
A1 Agho, Kingsley
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.16.22272510.abstract
AB The COVID-19 vaccines are being rolled out across all the Sub-Saharan Africa (SSA) countries, with countries setting targets for achieving full vaccination rates. The aim of this study was to compare the uptake of, resistance and hesitancy to the COVID-19 vaccine between SSA locally residents and in the diaspora. This was a cross-sectional study conducted using a web and paper-based questionnaire to obtain relevant information on COVID-19 vaccine acceptance. The survey items included questions on demography, uptake and planned acceptance or non-acceptance of the COVID-19 vaccines among SSAs. Multinomial logistic regression was used to determine probabilities of outcomes for factors associated with COVID-19 vaccination resistance and hesitancy among SSA respondents residing within and outside Africa. Uptake of COVID-19 vaccines varied among the local (14.2%) and diaspora (25.3%) residents. There was more resistance to COVID-19 vaccine among locals (68.1%) and across the sociodemographic variables of sex [ adjusted Relative Risk (ARR) =0.73, 95% CI; 0.58 – 0.93], primary/less [ARR =0.22, 95% CI; 0.12 – 0.40] and bachelor’s degree [ARR =0.58, 95% CI; 0.43 – 0.77] educational levels, occupation [ARR =0.32, 95% CI; 0.25 - 0.40] and working status [ARR =1.40, 95%CI; 1.06 - 1.84]. COVID-19 vaccine hesitancy was almost similar between locals and diasporas (17.7% and 17.8% respectively) significant only among healthcare workers [ARR =0.46, 95% CI; 0.16 – 1.35] in the diaspora after adjusting for the variables. Similarly, knowledge and perception of COVID-19 vaccine among locals were substantial, but only perception was remarkable to resistance [ARR =0.86, 95% CI; 0.82 – 0.90] and hesitancy [ARR =0.85, 95% CI; 0.80 – 0.90] of the vaccine. Differences exist in the factors that influence COVID-19 vaccine acceptance between local SSA residents and those in the diaspora. Knowledge about COVID-19 vaccines affects the uptake, resistance, and hesitancy to the COVID-19 vaccine. Information campaigns focusing on the efficacy and safety of vaccines could lead to improved acceptance of COVID-19 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors have no disclosuresAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to conduct the study was obtained from Humanities and Social Sciences Research Ethics Committee (approval #: HSSREC 00002504/2021) of the University of KwaZulu-Natal, Durban, South AfricaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this study has been included in the submission